Legal status Investigational ChemSpider 2278330 ChEMBL CHEMBL124363 | PubChem CID 3008897 UNII 6IE83O6NGA Molar mass 248.235 g/mol | |
 | ||
Synonyms 4'-ethynylstavudine, festinavir | ||
Censavudine (INN), is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. Censavudine is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Censavudine is a derivative of stavudine (d4T), but is less toxic. It was originally developed at Yale University.
Renaming
Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).
References
Censavudine Wikipedia(Text) CC BY-SA